Gonda, X
Eszlari, N
Anderson, I M
Deakin, J F W
Bagdy, G
Juhasz, G
Article History
Received: 30 June 2016
Revised: 30 August 2016
Accepted: 20 September 2016
First Online: 8 November 2016
Competing interests
: JFWD variously performed consultancy, speaking engagements and research for Bristol-Myers Squibb, AstraZeneca, Eli Lilly, Schering Plough, Janssen-Cilag and Servier (all fees are paid to the University of Manchester to reimburse them for the time taken); he also has share options in P1vital. IMA received consultancy fees from Alkermes, Lundbeck-Otsuka Ltd, Janssen-Cilag Ltd. The remaining authors declare no conflict of interest.